HUTCHMED Announces NDA Acceptance in China

Summary by AI BETAClose X

HUTCHMED announced that the China National Medical Products Administration has accepted and granted priority review status to its New Drug Application for sovleplenib for the treatment of warm antibody autoimmune hemolytic anemia in adult patients who have not responded adequately to glucocorticoid treatment. This acceptance is supported by positive Phase II/III study data, including a durable hemoglobin response rate in the Phase III portion and an overall response rate of 66.7% over 24 weeks in the Phase II portion, with a favorable safety profile. Sovleplenib, a novel oral spleen tyrosine kinase inhibitor, also received Breakthrough Therapy Designation from the NMPA in March 2026, underscoring its potential as a much-needed treatment option for patients with limited alternatives.

Disclaimer*

UK 100

Latest directors dealings